He invited Kolchinsky, a PhD student at Harvard University to join him due his technical expertise.

RA Capital has an in-house research group, named TechAtlas that creates its disease-specific maps.

[4] In 2009, RA Capital assets fell by 35.3% due to its large investment in Sequenom which lost 90% of its market value after it admitted it had falsified data on its tests for Down syndrome treatment.

[4][6] The firm made one of its first private investments in 2010 when it participated in a $15 million series C round for T2 Biosystems.

RA Capital was one of the firms and agreed to pay the largest amount out of them with disgorgement of $2.65 million, interest of $73,000 and a $905,000 penalty.